What is the recommended dosing, contraindications, and side effect profile of nitrofurantoin for treating uncomplicated lower urinary tract infections?

Nitrofurantoin for Uncomplicated Lower Urinary Tract Infections

Nitrofurantoin is a first-line agent for uncomplicated cystitis in women, dosed at 100 mg twice daily for 5 days, with excellent efficacy against common uropathogens and minimal collateral damage to gut flora. 1, 2

Recommended Dosing

For Acute Uncomplicated Cystitis in Women

• 100 mg twice daily for 5 days (macrocrystals, monohydrate, or prolonged-release formulations) 2
• Alternative: 50-100 mg four times daily for 5 days (macrocrystals only) 2
• Duration: 5 days is the clear recommendation based on robust evidence 1

The 5-day regimen at 100 mg twice daily has demonstrated superior clinical and microbiologic resolution compared to single-dose fosfomycin (70% vs 58% clinical resolution at 28 days) 3. While some UK guidelines suggest 3-day courses, there is limited direct evidence supporting this shorter duration 4.

For Men with UTI

• Treatment duration should be 7 days minimum (not 5 days as in women) 2
• Consider that UTIs in men are generally considered complicated

For Prophylaxis of Recurrent UTI

• 50 mg once daily is preferred over 100 mg for prophylaxis 5
• The 50 mg dose provides equivalent UTI prevention with significantly fewer adverse effects (lower hazard ratios for cough, dyspnea, and nausea) 5

Critical Contraindications

Absolute Contraindications

• Creatinine clearance <30 mL/min (some sources say <60 mL/min) 6
• Last trimester of pregnancy (third trimester) 2
• G6PD deficiency - risk of hemolytic anemia 6
• Infants under 1 month of age 6

Relative Contraindications/Cautions

• Elderly patients - increased risk of peripheral neuropathy and pulmonary reactions 6
• Diabetes mellitus - increased peripheral neuropathy risk 6
• Anemia - increased peripheral neuropathy risk 6
• Vitamin B deficiency - increased peripheral neuropathy risk 6
• Debilitating diseases - increased peripheral neuropathy risk 6

Critical caveat: Nitrofurantoin should NOT be used for pyelonephritis or suspected upper tract infections, as it does not achieve therapeutic serum or tissue concentrations 1, 7.

Side Effect Profile

Common (Dose-Related, Reversible)

• Gastrointestinal: Nausea (3%), diarrhea (1%), anorexia, abdominal pain 6, 3
• These can be minimized by dose reduction or taking with food

Serious Pulmonary Reactions (Most Important)

Acute Pulmonary Reactions (within first week):

• Fever, chills, cough, chest pain, dyspnea
• Pulmonary infiltrates, pleural effusion, eosinophilia
• Reversible with immediate cessation 6

Chronic Pulmonary Reactions (after ≥6 months continuous use):

• Insidious onset: malaise, dyspnea on exertion, cough
• Diffuse interstitial pneumonitis or fibrosis
• May be IRREVERSIBLE - permanent pulmonary impairment possible 6
• Risk increases dramatically if not recognized early

Neurologic Reactions

• Peripheral neuropathy - may become severe or irreversible; fatalities reported 6
• Risk factors: renal impairment, anemia, diabetes, electrolyte imbalance, vitamin B deficiency
• Other: dizziness, headache, drowsiness, vertigo
• Rare: benign intracranial hypertension, optic neuritis, psychotic reactions

Hepatic Reactions (Rare)

• Hepatitis, cholestatic jaundice, chronic active hepatitis, hepatic necrosis 6

Hematologic

• Hemolytic anemia (especially with G6PD deficiency)
• Agranulocytosis, leukopenia, thrombocytopenia, megaloblastic anemia
• Most resolve with cessation; aplastic anemia reported rarely 6

Hypersensitivity

• Most frequent spontaneously-reported adverse events worldwide 6
• Lupus-like syndrome, angioedema, Stevens-Johnson syndrome (rare)
• Anaphylaxis, urticaria, drug fever

Clinical Advantages

Why nitrofurantoin is first-line 1, 8:

• Achieves high urinary concentrations with minimal systemic exposure
• Minimal collateral damage to gut microbiome (unlike fluoroquinolones or broad-spectrum agents)
• Low resistance rates despite 60+ years of use
• Spares more systemically active agents for other infections
• Active against multidrug-resistant uropathogens including ESBL-producing E. coli

Key Monitoring Points

• Do NOT use for suspected pyelonephritis or bacteremia - inadequate serum levels 1, 7
• Monitor for pulmonary symptoms during therapy, especially if used >6 months
• Assess renal function before prescribing - contraindicated in any degree of renal impairment per some guidelines 6
• No routine post-treatment cultures needed if asymptomatic 2
• If symptoms persist or recur within 2 weeks, obtain culture and switch to different agent for 7 days 2